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Retinoic acid and arsenic trioxide sensitize acute promyelocytic
leukemia cells to ER stress
S Masciarelli1, E Capuano1, T Ottone2, M Divona2, S De Panfilis3, C Banella4, NI Noguera2,4, A Picardi5, G Fontemaggi6, G Blandino6,
F Lo-Coco2,4 and F Fazi1
Retinoic acid (RA) in association with chemotherapy or with arsenic trioxide (ATO) results in high cure rates of acute promyelocytic
leukemia (APL). We show that RA-induced differentiation of human leukemic cell lines and primary blasts dramatically increases
their sensitivity to endoplasmic reticulum (ER) stress-inducing drugs at doses that are not toxic in the absence of RA. In addition, we
demonstrate that the PERK pathway, triggered in response to ER stress, has a major protective role. Moreover, low amounts of
pharmacologically induced ER stress are sufficient to strongly increase ATO toxicity. Indeed, in the presence of ER stress, ATO
efficiently induced apoptosis in RA-sensitive and RA-resistant APL cell lines, at doses ineffective in the absence of ER stress. Our
findings identify the ER stress-related pathways as potential targets in the search for novel therapeutic strategies in AML.
Leukemia (2018) 32, 285–294; doi:10.1038/leu.2017.231
INTRODUCTION
Acute promyelocytic leukemia (APL) is characterized by the
chromosomal translocation t(15;17) resulting in the expression
of fusion protein PML-RARα,1 which impedes the differentiation
program driven by RARα, and arrests the cells at the promyelocytic
stage. APL is successfully treated by all-trans retinoic acid (RA) in
combination with arsenic trioxide (ATO) or by RA and
chemotherapy.2 RA is able to activate RARα-mediated transcrip-
tion, thereby resuming differentiation,3 and to target PML-RARα
for degradation.4 ATO targets the PML moiety of the hybrid
protein synergizing with RA in PML-RARα degradation and induces
apoptosis of APL blasts via caspase and reactive oxygen species
(ROS)-mediated mechanisms.4 Two randomized studies have
recently shown the advantage of the RA-ATO combination over
conventional RA plus chemotherapy establishing the former
approach as the new standard at least in non-high-risk
patients.5,6 Despite showing a considerably improved safety
profile, either RA or ATO are not devoid of toxicity, with the most
important and potentially life-threatening one being the so-called
RA differentiation syndrome.2,5–7
RA drives leukemic blasts toward granulocytic differentiation,
characterized by the production of secretory granules. Increased
secretory protein folding demands in the endoplasmic reticulum
(ER) can cause imbalance between the folding capacity and the
amount of unfolded client proteins, defined as ER stress. To cope
with stress, the ER triggers a series of pathways, emanating from
three ER transmembrane receptors, ATF6, IRE1α and PERK,
collectively known as the unfolded protein response (UPR). The
UPR aims at restoring protein folding homeostasis8 but under
conditions of prolonged stress, it activates pro-apoptotic signaling
pathways among which the ATF4/CHOP/GADD34 axis has a major
role.9,10 We hypothesized that the RA-induced differentiation of
APL cells and the consequent rise in the ER activity render them
particularly sensitive to ER stress, shifting the balance of the UPR
from pro-survival to pro-apoptotic. Here we show that the APL cell
line NB4 and primary human APL cells become sensitive to
pharmacologically generated ER stress upon differentiation
induction by RA and that such sensitivity mainly involved the
PERK pathway. Furthermore, we observed a strong synergistic
cytotoxic effect of ATO and the ER stress-inducing drug
Tunicamycin (Tm), in both RA-sensitive and RA-resistant APL
cell lines.
MATERIALS AND METHODS
Cell lines and primary leukemic blasts cultures and treatments
The drug doses to treat NB4 and NB4-R4 cell lines were as follows: 10 nM
RA, 50ng/ml Tm, 17 μM Guanabenz Acetate, 300 nM GSK2606414 (GSK), 200
or 500 nM ATO and 20 mM N-acetyl-cysteine. Bone marrow samples were
seeded in Methocult 4035 medium with or without 10 nM RA, 50 ng/ml Tm
and 500 nM ATO alone or in combination.
Cell death, cell cycle and cell differentiation
Cell death was evaluated by the propidium iodide exclusion assay. Cell
cycle of NB4 and NB4-R4, of APL primary blasts and of healthy bone
marrow cells, growth in Methocult media for 11 or 8 days respectively, was
analyzed by flow cytometry. Cell differentiation was assessed by
morphological analysis of cytospin preparations stained with Wright–
Giemsa stain and by flow cytometry after staining with antibody against
myeloid markers (CD11b and CD14).
Immunofluorescence analysis
Confocal microscopy was performed on cytospin preparations stained first
with primary anti-calreticulin, anti-calnexin, anti-BiP or anti-PML antibodies,
then with anti-rabbit Alexa Fluor-488 or anti-mouse Alexa Fluor-555.
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Quantitative reverse transcription-PCR
Quantitative RT-PCR was analyzed by the ΔΔCt method using histone 3 as
endogenous control for standardization.
Western blotting
Twenty to 40 μg of total protein extract were separated by SDS-
polyacrylamide gel electrophoresis, with or without the addition of
50 mM DDT followed or not by boiling 5′ for western blotting in reducing
or non-reducing conditions, respectively.
Lentiviral transduction
Lentiviral particles containing the short hairpin RNA targeting CHOP or the
non-silencing control sequence were prepared in HEK293 cells using the
GIPZ lentiviral short hairpin RNA and the packaging vectors described in
De Palma et al.46 The cells successfully transduced were selected by the
addition of puromycin in the culture medium for 48 h.
RESULTS
RA-induced granulocytic differentiation sensitizes NB4 cells to ER
stress
To assess whether RA-driven differentiation would sensitize APL cells
to ER stress, we treated the human APL cell line NB4 with RA and the
N-glycosylation inhibitor Tm, an ER stress inducer. After 72 h of
combined treatment, the cells reached a much lower cellular density
than the untreated control (Supplementary Figure S1a). Although
the effect on the proliferation rate was negligible in the presence of
RA plus Tm (Supplementary Figure S1b), we observed a high
percentage of apoptotic cells at 72 h (Figure 1a and Supplementary
Figure S1c), using low doses of Tm that alone exhibited only a slight
effect on cellular density and none on cell viability. A drug washout
experiment suggested that the cells that did not respond to RA plus
Tm were able to recover (Supplementary Figure S1d). We obtained
similar results generating ER stress with the sarco/endoplasmic
reticulum Ca2
+-ATPase inhibitor Thapsigargin, ruling out specific
effects of Tm (Supplementary Figure S1e). Low concentrations of RA
were able to affect NB4 cells resistance to Tm or Tg. Indeed, we used
a physiological concentration of RA that was sufficient to induce
differentiation (although incomplete), as indicated by the slower
proliferation rate and by the increased expression of the granulocytic
marker CD11b (Supplementary Figures S1a and f). Morphological
analysis confirmed the differentiation of RA-induced cells, evidenced
by cytosol enlargement and decreased basophilia with respect to
control cells (Figure 1b). We observed that cytosol enlargement was
even more evident in the cells treated with RA plus Tm. As ER stress
causes ER dilatation, we examined its morphology performing
immunofluorescence staining of the ER chaperones Calreticulin and
HSPA5/BiP (Figure 1c). As expected during granulocytic differentia-
tion, we observed early expansion of the ER followed by its
regression. Cells treated with Tm alone showed swelled ER at 48 h
that reverted to normal appearance at 72 h, in accordance with
resolution of stress. On the contrary, induction of ER stress in
differentiating cells caused further expansion of the ER up to 72 h
following treatments. These results show that RA-induced differ-
entiation strongly sensitizes the APL cells NB4 to amounts of ER
stress that are easily managed in growth conditions.
RA sensitizes APL primary blasts to ER stress
Next, it was important to determine whether freshly isolated
differentiating human primary APL blasts showed increased
sensitivity to ER stress. Colony-forming unit assays revealed that
RA-treated primary cells produced smaller colonies upon induc-
tion of ER stress in comparison with cells treated with RA and Tm
alone or untreated (Figure 2a and Supplementary Figure S2a),
although the total number of colonies was the same (data not
shown). Importantly, treatment with RA and Tm in combination
showed no toxicity on mononucleated bone marrow cells
obtained from healthy donors (Figure 2a and Supplementary
Figure S3a), indicating higher sensitivity of APL cells to ER stress.
We found no difference in the differentiation pattern (Figure 2b
and Supplementary Figure S2c) but a slower proliferation rate
(Supplementary Figure S2b) in APL cells treated with RA plus Tm
relatively to those treated with RA only. Morphological analysis
revealed the presence of numerous vacuoles in most of the APL
cells treated with RA and Tm, suggesting apoptosis, but not in
healthy cells (Figure 2b and Supplementary Figure S2c).
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Figure 1. RA-induced differentiation sensitizes NB4 cells to ER stress. (a) NB4 cells treated with 10 nM RA and 50 ng/ml Tm, alone or
in combination as indicated, were analyzed for propidium iodide (PI) uptake as an indication of cell death (n= 3± s.e.m.; Student’s T-test
***P-valueo0.005; full analysis of variance (ANOVA) reported in Supplementary Table 1). (b) Morphological analysis of NB4 treated for 72 h.
(c) The same cells were stained with anti-calreticulin (CARL) and anti-GRP78 (BiP) antibodies, and analyzed by confocal microscopy.
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Accordingly, cell cycle analysis demonstrated a higher percentage
of apoptotic cells in the APL samples treated with RA and Tm than
in those treated with RA alone (Figure 2c and Supplementary
Figure S3b). As a further control of toxicity of the combination of
RA and Tm on normal cells, peripheral blood mononucleated cells
and healthy bone marrow cells were seeded in liquid culture with
the addition or not of RA and Tm alone or in combination. After
72 h cell death and the relative percentage of lymphocytes and
myeloid cells were evaluated by flow cytometry, finding no
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Figure 2. RA sensitizes APL primary blasts to ER stress. (a) APL blasts isolated from three patients’ bone marrow (APL1, APL2 and APL3) were
treated in semisolid medium for 8 days. Bone marrow mononucleated cells isolated from two healthy donors (BM1 and BM2) were treated in
semisolid medium for 4 days. The box plots report the distribution of the number of cells forming the colonies (APL1 n⩾ 40, APL2 and APL3
n⩾ 200 for each treatment; Student’s T-test *P-valueo0.05, ***P-valueo0.005; BM1 n= 200; BM2 n⩾ 120; analysis of variance (ANOVA)
presented in Supplementary table 1). (b) Morphological analysis of patient APL4 cells and of healthy donor BM1 cells isolated from 8 days
colonies obtained as in a. The black arrows indicate cell vacuoles, MΦ macrophages, the inset in BM1 RA panel delimits cells from another
field. Quantification of the different cell types and of vacuolation is shown in Supplementary Figure 2c. (c) Cell cycle analysis of the same cells
to evaluate cell death as subG1 DNA content. (d) Protein extracts of cells isolated from patient APL4, treated in semisolid medium for 4 days,
were analyzed by western blot analysis for the expression of p53 protein. GAPDH was used as loading control. (e) Total RNA from cells isolated
from patient APL5, treated as in d, with the addition of ATO (see below, Figure 6), for 4 days were analyzed by quantitative reverse
transcriptase-PCR (qRT-PCR) for the expression of the p53 targets PIG3, NOXA and p53AIP1.
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Figure S3c and d). Previous studies have demonstrated in both
APL murine models and APL patients that RA- or ATO-dependent
degradation of PML-RARα and the consequent re-emergence of
PML nuclear bodies, activates tumor protein p53, a condition
necessary to achieve disease eradication in mouse.11 The p53
pathway is activated in response to multiple stresses, including ER
stress.12 Therefore, we analyzed the p53 pathway activation in
primary APL samples, expressing wt p53 (Supplementary Table 2),
in response to RA and/or ATO and Tm combined treatment. We
observed that although there was no activation of the pathway
with RA or Tm alone at the low doses used in our experiments, the
combination of the two drugs stabilized the p53 protein and
increased the expression of the p53 targets NOXA, PIG3 and p53AIP
(Figures 2d and e). Altogether, these observations indicate that
primary APL blasts, treated ex vivo, are more sensitive to ER stress
upon differentiation induced by RA.
Increased sensitivity of differentiating NB4 cells to ER stress
correlates with the strength of UPR activation
To clarify the molecular mechanisms underlying the inability of
differentiating NB4 to cope with low levels of ER stress, we
investigated UPR activation. We measured the expression of genes
generally upregulated by the UPR. Treatment with Tm induced the
expression of most of the UPR markers examined in cells cultured
in growth medium but the expression of CHOP and BiP was
significantly increased in differentiating cells (Figure 3a). CHOP
protein expression peaked 24 h upon treatment decreasing
completely at later time points. BiP protein expression increased
in a similar manner in cells treated with Tm alone or with Tm and
RA up to 48 h, decreasing at 72 h in the cells treated with Tm only.
On the contrary, its expression remained higher in cells under-
going combined treatment (Figure 3b). As BiP is a main ER
chaperone, binding unfolded proteins to retain them in the ER,13
an increase in ER stress would cause BiP to form more complexes
with unfolded client proteins. Indeed, western blot analysis in non-
reducing conditions revealed the presence of BiP-containing
complexes in the cells treated with RA and Tm (Figure 3c). These
observations, together with the swelling pattern of the ER
described in Figure 1c, support the conclusion that differentiating
NB4 cells are not able to overcome the stress induced by Tm
compared with those not stimulated by RA. Moreover, the higher
expression of the pro-apoptotic protein CHOP compared with UPR
factors mostly involved in the recovery of homeostasis, suggests a
shift of the response from pro-survival to pro-apoptotic.
To understand the contribution of CHOP in the apoptosis of
NB4 cells treated with RA and Tm, we generated NB4 cells stably
expressing a short hairpin against CHOP mRNA (NB4-shCHOP)
(Supplementary Figure S4a and b). These cells were more resistant
to the combined treatment than the non-silencing-control cells
(NB4-NSC) (Figures 3d and e). Although we were not able to
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Figure 3. Increased sensitivity of differentiating NB4 cells to ER stress correlates with the strength of UPR activation. (a) Quantitative reverse
transcriptase-PCR (qRT-PCR) for the expression of UPR target genes from NB4 samples treated for 24 h (n= 4± s.e.m.; Student’s T-test
*P-valueo0.05, **P-valueo0.02, ***P-valueo0.005; analysis of variance (ANOVA) presented in Supplementary Table 1). (b) Western blot
analysis of total protein extracts from NB4 cells for CHOP and BiP proteins. Actin was used as loading control. The histogram reports the
average quantification of BiP protein (n= 3± s.e.m.). (c) Western blotting in non-reducing conditions of total protein extracts from NB4 cells
treated for 72 h. A shorter exposure is shown on the left, a longer one on the right. The black arrowheads point to BiP complexes. GAPDH was
used as loading control. (d) Growth curve and (e) propidium iodide (PI) uptake analysis of NSC and shCHOP NB4 cells (n= 2± s.e.m., ANOVA
analysis in Supplementary Table 1).
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suggest that it has a role in driving ER stress-related death of
differentiating NB4 cells.
Attenuation of global translation protects differentiating NB4 cells
from ER stress-induced death
We then wanted to understand the role had by the different UPR
pathways in sensitizing differentiating NB4 to ER stress. Thus, we
repeated the experiments described above in the presence of
specific inhibitors of UPR key signaling proteins. Upon activation,
PERK phosphorylates the translation initiation factor eIF2α, thus
attenuating global protein synthesis in order to reduce the load of
newly synthetized proteins into the ER. Phosphorylation of eIF2α
leads to selective translation of the transcription factor ATF4 that
regulates the expression of genes involved in protein folding,
autophagy, antioxidant response and apoptosis. ATF4 targets
CHOP that in turn promotes the expression of PPP1R15A/GADD34,
the regulatory subunit of the protein phosphatase PP1c that de-
phosphorylates eIF2α restoring translation.14 We inhibited PERK
with the GSK2606414 (GSK) compound15 and GADD34 with its
inhibitor Guanabenz.16,17 Inhibition of PERK further increased the
sensitivity of NB4 differentiating cells to ER stress, whereas
Guanabenz blunted the toxicity of the combination of RA and
Tm (Figure 4a and Supplementary Figure S5a). The ratio between
cleaved and uncleaved caspase 3 confirmed a higher apoptotic
rate in NB4 cells exposed to RA and Tm in the presence of GSK
than in those treated with RA and Tm only (Figure 4b). With the
exception of the downregulation of CHOP and BiP expression, we
noticed a slightly increased activation of the UPR following PERK
inhibition. Inhibition of GADD34 significantly reduced the expres-
sion of UPR target genes, suggesting reduced ER stress (Figure 4c).
Inhibition of IRE1α by the 4 μ8 compound showed no significant
effects (Supplementary Figure S5b and c) implying that Ire1α
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Figure 4. Attenuation of global translation protects differentiating NB4 cells from ER stress-induced death. (a) Propidium iodide (PI) uptake
analysis of NB4 cells treated with RA and/or Tm, in the absence (nil) or presence of the PERK inhibitor GSK (300 nM), or of the GADD34 inhibitor
Guanabenz (17 μM) (n= 4± s.e.m.; Student’s T-test *P-valueo0.05, **P-valueo0.02; analysis of variance (ANOVA) presented in Supplementary
Table 1). (b) Western blot analysis to assess the ratio between cleaved and uncleaved caspase-3. (c) Quantitative reverse transcriptase-PCR
(qRT-PCR) for UPR target genes from samples treated as in (a) (n= 3± s.e.m. at 24 h; n= 2± s.e.m. at 72 h; ANOVA analysis in Supplementary
Table 1).
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opposite effects of PERK or GADD34 inhibition, we conclude that
the attenuation of translation is important for survival of
differentiating NB4 cells in the context of ER stress.
ER stress does not impair RA-driven PML-RARα degradation
The oncogenic fusion protein PML-RARα modifies the function of
the transcription factor RARα and of the tumor suppressor PML
that is the central component of the PML nuclear bodies (PML-
NBs).18 By heterodimerizing with PML, PML-RARα disrupts the
PML-NBs and its degradation, driven by RA, restores PML functions
and NB structure. As PML-RARα degradation is dependent both on
the ubiquitin–proteasome system and on autophagy, and these
cellular processes are highly interconnected with the ER functions,
we wanted to assess whether drug-induced ER stress in NB4 cells
treated with RA could interfere with PML-RARα degradation and
PML nuclear distribution. Cells treated with RA or with RA and Tm
similarly degraded PML-RARα (Figure 5a). Analysis of PML nuclear
distribution by immunofluorescence revealed a slight difference in
the microspeckled pattern between samples treated with RA
alone and those treated with RA plus Tm (Figure 5b): some of the
cells treated with RA showed less microspeckles, in comparison
with control or Tm-treated cells, suggesting initiation of NB
formation, whereas the cells undergoing combined treatment
showed clustering of PML/PML-RARα at the nucleus periphery.
However, when we used the pharmacological dose of 1 μM RA the
combination with Tm did not affect PML-NBs generation
(Supplementary Figure S6). PML-NB genesis depends on inter-
molecular disulphide bonds formation and this process is
promoted by the presence of ROS;18,19 thus, both PML and PML-
RARα are prone to disulphide bond-dependent aggregation and
oxidative stress. As the UPR generates oxidative stress we
investigated the level of PML-RARα and PML aggregation in NB4
cells treated with 10 nM RA alone or with Tm by non-reducing
western blotting. We found that a fraction of PML and to a lesser
extent of PML-RARα, formed high-molecular-weight complexes in
differentiating cells in conditions of ER stress (Figure 5c). This
finding could explain the different distribution of PML/PML-RARα
observed by immunofluorescence. Altogether, these results
indicate that ER stress does not affect PML-RARα degradation
but suggest that it generates a more oxidative environment.
ER stress and ATO exhibit synergistic toxicity in RA-sensitive NB4
and in RA-resistant NB4-R4 cells
ER stress is closely related to oxidative stress.20 The ATF4/CHOP
axis in particular has been shown to induce UPR-related cell death
by increasing ROS levels, among other mechanisms.14 As the
mechanisms of action of ATO involve generation of ROS,18,21 we
wondered whether ATO could further sensitize cells treated with
RA and Tm, possibly by exacerbating oxidative stress. Thus, we
treated NB4 cells with RA and/or Tm as described above, in the
presence or absence of sub-lethal doses of ATO (200 or 500 nM).
ATO and Tm alone did not significantly affect cell viability whereas
treatment with both drugs together resulted in apoptotic cell
death, independently from the presence or absence of RA
(Figure 6a and Supplementary Figures S7a and b). Importantly,
the combined treatments resulted not toxic on healthy peripheral
blood mononucleated cell and bone marrow mononucleated cells
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Figure 5. ER stress does not impair RA-driven PML-RARα degradation. (a) Western blot analysis of total extracts from NB4 cells with 10 nM RA
with or without 50 ng/ml Tm, decorated with an anti-PML antibody. The empty arrowhead points to PML-RARα, the other bands are different
PML isoforms. Actin was used as loading control. (b) Confocal microscopy analysis of NB4 cells treated for 72 h as in (a) stained with anti-
Calnexin (CNX, green) and anti-PML PGM3 (red) antibodies. The white arrows point to differentiating cells with a reduced amount of
microspeckles and an irregularly shaped nucleus indicating differentiation. (c) Western blotting in non-reducing conditions of total protein
extracts NB4 cells treated as in a for 72 h decorated with an anti-RARα and, after stripping, with an anti-PML antibody. GAPDH was used as
loading control.
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the toxicity of Tm and ATO whereas inhibition of GADD34 by
Guanabenz protected the cells. Not surprisingly, considering the
strong link between oxidative and ER stress, ATO amplified the
UPR in response to Tm (Figure 6b). Direct measurement of ROS
levels showed that Tm and ATO alone, both increased ROS levels
at 48 h. Likewise, Tm and ATO with or without RA, and RA and Tm
increased ROS levels after 48 h of treatment. Interestingly,
although at 72 h the cultures treated with each drug alone
recovered from the oxidative stress, those treated with the various
combinations did not (Figure 6c). Importantly, perturbation of the
PERK pathway by GSK or Guanabenz caused augmented amounts
of ROS especially in the cells undergoing combined treatments at
48 h. However, at 72 h, in the presence of GSK the ROS levels
remained significantly increased, whereas in the presence of
Guanabenz the levels returned comparable to those observed in
control cells. Analysis of the expression of heme oxigenase-1 (HO-1)
mRNA, a key element in the response to oxidative stress,22
confirmed that inhibition of the PERK pathway leads to an
amplified response to Tm in combination with ATO (Figure 6d). To
understand the importance of oxidative stress in driving apoptosis
in this context, we repeated the same experiments in the presence
or absence of the reducing agent N-acetyl cysteine. Strikingly, the
presence of N-acetyl cysteine was sufficient to completely
counteract the toxic effects of Tm plus ATO and also of Tm plus
RA, indicating that generation of oxidative stress is a main driving
mechanism leading to apoptosis triggered by ER stress (Figure 6e).
As we did not observe additional toxicity following treatment
with the combination of RA with Tm plus ATO, we tested the
sensitivity of RA-resistant cells NB4-R4 (R4) to the different
treatments. Surprisingly, even though they did not respond to
RA alone, as expected and verified by morphological analysis, they
nonetheless appeared differentiated in the presence of RA plus
Tm (Figure 7a). Indeed the upregulation of the UPR target genes
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Figure 6. ER stress and ATO exhibit synergic toxicity in NB4 cells. NB4 cells were treated with 10 nM RA and/or 50 ng/ml Tm and/or 500 nM ATO
as indicated, in the absence (nil) or presence of the PERK inhibitor GSK (300 nM), or of the GADD34 inhibitor Guanabenz (17 μM) for the
indicated time points. (a) Propidium iodide (PI) uptake analysis after 72 h of treatment (n= 2± s.e.m.; Student’s T-test *P-value⩽ 0.05; analysis
of variance (ANOVA) in Supplementary Table 1, see results for Supplementary Figure S6a). (b) Quantitative reverse transcriptase-PCR (qRT-PCR)
analysis for the expression of the UPR genes CHOP, BiP and sXBP1 in samples treated for 24 h. (c) Evaluation of ROS levels by flow cytometry
following loading of the CM-H2DCFDA oxidative stress indicator. The histogram reports the mean fluorescence values (MFI). (d) qRT-PCR for
the expression of the Heme-Oxigenase-1 (HO-1) in the same samples (e) PI uptake analysis of cells treated with the addition of 20 mM N-acetyl
-cysteine (NAC) for 72 h.
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showed that even though this sub-clone has lost regulation of part
of the RA-signaling pathway it still retains retinoid induction of
some targets.23 Remarkably, R4 cells proved very sensitive to the
combination of Tm plus ATO, even when this was used at 200 nM
(Figure 7c and Supplementary Figure S7a), and such sensitivity
was exacerbated by the inhibition of PERK by GSK, as it was in the
case of Tm alone or Tm plus RA. As observed in NB4 cells,
inhibition of GADD34 by Guanabenz resulted in total protection
from toxicity. Owing to the very high percentage of cell death
following treatments, the ROS measurements did not provide
clear data (data not shown). However, analysis of the expression of
heme oxigenase-1 (Figure 7d) and the striking protection
provided by N-acetyl cysteine (Figure 7e) prove that the apoptotic
effects of the combinations of RA, Tm and ATO, amplified by GSK,
depend on the generation of oxidative stress. Both in NB4 and
NB4-R4 we found that in the presence of ER stress there were no
differences in PML-RARα and PML degradation induced by ATO at
72 h (Supplementary Figure S7c). In conclusion, these data
indicate that the combined effect of low doses of ER stress
induced by Tm and of oxidative stress induced by ATO, results in
increased toxicity in APL cells, independently from their ability to
respond to RA.
DISCUSSION
The primary aim of the UPR is to restore cellular homeostasis24 but
in the event of a prolonged ER stress the response shifts from pro-
survival to pro-apoptotic.10 There has been a growing interest in
the role of the UPR in cancer25,26 with the idea of aggravating ER
stress to target tumor cells that use the UPR as an adaptive
response.27,28 Importantly, the UPR is activated in about 25% of
AML patients,29,30 identifying a subpopulation where aggravation
of ER stress in combination with the existing therapies could be
particularly beneficial. How to induce ER stress in vivo is still to be
defined. Tm presents general toxicity in vivo31 but low amounts of
Tm can be selectively effective on tumor cells in mice.32 Notably,
we used a dose of Tm not toxic for the same cells in the absence
of RA and 20–100 times lower than the doses commonly used to
induce lethal ER stress in cell lines.9,17,33 Moreover, drugs targeting
different pathways can indirectly exacerbate ER stress and some of
these already provided interesting results in AML.34–37 Another
way of aggravating ER stress is to inhibit the pathways having a
protective role during the response. We found that a direct
inhibition of PERK strongly worsened the toxicity of the
combination of RA/ATO and Tm, whereas inhibition of GADD34
was highly protective. Transient inhibition of general translation
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Figure 7. ER stress and ATO exhibit synergic toxicity in RA-resistant NB4-R4 cells. NB4-R4 cells were treated with 10 nM RA and/or 50 ng/ml Tm
and/or 500 nM ATO as indicated, in the absence (nil) or presence of the PERK inhibitor GSK (300 nM), or of the GADD34 inhibitor Guanabenz
(17 μM) for the indicated time points. (a) Morphological analysis of cells treated for 72 h. (b) Quantitative reverse transcriptase-PCR (qRT-PCR)
analysis for the expression of the UPR genes CHOP, BiP and sXBP1 in samples treated for 24 h. (c) Propidium iodide (PI) uptake
analysis following 72 h of treatment (n= 2± s.e.m.; Student’s T-test **P-valueo0.02, ***P-valueo0.005; analysis of variance (ANOVA) in
Supplementary Table 1, see results for Supplementary Figure S6b). (d) qRT-PCR for the expression of the Heme-Oxigenase-1 (HO-1) in the same
samples. (e) PI uptake analysis of cells treated with the addition of 20 mM N-acetyl-cysteine (NAC) for 72 h.
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survival mechanism upon UPR activation9 explaining why the use
of Guanabenz reduced ER stress and impeded cell death.
Inhibition of PERK and of GADD34 both resulted in decreased
CHOP expression but had opposite effects on cell survival,
suggesting differing mechanisms of action. In the case of GADD34
inhibition eIF2α phosphorylation is favored and protein synthesis
downregulated. This causes a strong reduction of ER and oxidative
stress, and promotes survival; the decrease in ER stress shuts down
the UPR leading to reduced UPR target gene expression, including
CHOP. In contrast, PERK inhibition hinders eIF2α phosphorylation
(and CHOP expression that is directly downstream this pathway),
leading to sustained protein translation with consequent increase
of ER and especially oxidative stress. Our findings are in
accordance with those from the laboratories of Randal Kaufman
and Anne Bertolotti, who elegantly demonstrated the prominent
role of P-eIF2α-mediated inhibition of protein synthesis in survival
after ER stress.9,17
APL is curable with therapies combining RA plus chemotherapy
or RA plus ATO. These strategies result in very high rates of long-
term remission, however both RA and ATO are associated with
some adverse events including differentiation syndrome, which
represents a potentially fatal complication.2,5–7 Combining RA with
ER stress we obtained malignant promyelocytic cell death using a
dose of RA hundred times lower than the therapeutic reference
range.38 Furthermore, we obtained a strong cytotoxic effect of ATO
in combination with Tm using ATO doses 2 to 10 times lower than
the therapeutic reference.39 Indeed, we found no toxicity of the
combined treatments on bone marrow mononucleated cells from
healthy donors (Figures 2a and b, and Supplementary Figure S3).
RA- and ATO-mediated PML-RARα degradation, via the proteasome
system40,41 and autophagy,4,18,42,34 is the underlying mechanisms
by which APL is cured.4,41,43 The possible overload of the
proteasome due to ER stress could hamper PML-RARα degradation
but this was not the case in our experimental conditions. APL
represents a paradigm of targeted therapy but retinoids proved
unsuccessful in non-APL AML.44 Importantly, we found that RA
sensitized the myeloblastic leukemia cell line HL6045 to ER stress
induced by Tm (Supplementary Figure S8), although the molecular
mechanisms of action were different from those observed in NB4
cells. Even though these observations need to be investigated
further, they suggest the possibility that some types of non-APL
cells could also respond to RA in combination with ER stress.
In conclusion, this work explored new strategies that could lead
to the development of less toxic and more effective therapies,
exploiting the idea of combining different sources of cellular stress
to target malignant promyelocytes.
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